JP2023545274A5 - - Google Patents

Info

Publication number
JP2023545274A5
JP2023545274A5 JP2023521512A JP2023521512A JP2023545274A5 JP 2023545274 A5 JP2023545274 A5 JP 2023545274A5 JP 2023521512 A JP2023521512 A JP 2023521512A JP 2023521512 A JP2023521512 A JP 2023521512A JP 2023545274 A5 JP2023545274 A5 JP 2023545274A5
Authority
JP
Japan
Prior art keywords
optionally substituted
dione
dioxopiperidine
amino
isoindoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023521512A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023545274A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/122530 external-priority patent/WO2022073469A1/en
Publication of JP2023545274A publication Critical patent/JP2023545274A/ja
Publication of JP2023545274A5 publication Critical patent/JP2023545274A5/ja
Pending legal-status Critical Current

Links

JP2023521512A 2020-10-07 2021-10-07 癌を処置する化合物および方法 Pending JP2023545274A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/119834 2020-10-07
CN2020119834 2020-10-07
PCT/CN2021/122530 WO2022073469A1 (en) 2020-10-07 2021-10-07 Compounds and methods of treating cancers

Publications (2)

Publication Number Publication Date
JP2023545274A JP2023545274A (ja) 2023-10-27
JP2023545274A5 true JP2023545274A5 (enExample) 2024-10-16

Family

ID=81125595

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023521512A Pending JP2023545274A (ja) 2020-10-07 2021-10-07 癌を処置する化合物および方法

Country Status (5)

Country Link
US (1) US20240050428A1 (enExample)
EP (1) EP4225749A4 (enExample)
JP (1) JP2023545274A (enExample)
CN (1) CN116583509A (enExample)
WO (1) WO2022073469A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024504932A (ja) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス, インコーポレイテッド イソインドリノン化合物
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
MX2023013961A (es) * 2021-10-01 2023-12-11 Nextgen Bioscience Co Ltd Nuevos derivados de la piperidina y composiciones farmaceuticas que los contienen, para inhibir la autotaxina.
KR20250004694A (ko) * 2022-04-06 2025-01-08 클루젠 (상하이), 인크. 암 치료를 위한 조성물 및 방법
US20250361239A1 (en) * 2022-06-10 2025-11-27 Zhuhai Yufan Biotechnologies Co., Ltd. Protein degraders and uses thereof
WO2024015855A1 (en) * 2022-07-13 2024-01-18 Monte Rosa Therapeutics, Inc. COMBINATION THERAPY COMPRISING GSPT1-DIRECTED MOLECULAR GLUE DEGRADERS AND PI3K/AKT/mTOR PATHWAY INHIBITORS
WO2024032689A1 (zh) * 2022-08-10 2024-02-15 标新生物医药科技(上海)有限公司 基于异吲哚啉取代戊二酰亚胺骨架的化合物及其应用
CN115636811A (zh) * 2022-08-17 2023-01-24 成都分迪药业有限公司 异吲哚啉苄胺衍生物的合成方法
JP2025531869A (ja) 2022-09-09 2025-09-25 イノヴォ セラピューティクス、インコーポレイテッド CK1αおよびDUAL CK1α/GSPT1分解化合物
WO2024099441A1 (en) * 2022-11-11 2024-05-16 Jingrui Biopharma (Shandong) Co., Ltd. Bromodomain and extra-terminal (bet) protein degrader
KR20250121114A (ko) 2022-12-16 2025-08-11 아스트라제네카 아베 2,6,9-삼치환된 퓨린
EP4685141A1 (en) * 2023-03-21 2026-01-28 Shanghai Helioson Pharmaceutical Co., Ltd. Isoindoline derivative, benzoindole derivative and use thereof
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds
WO2025231420A1 (en) * 2024-05-03 2025-11-06 Albert Einstein College Of Medicine Small molecule degraders of soluble epoxide hydrolase
CN121620373A (zh) * 2024-07-26 2026-03-06 上海超阳药业有限公司 苯并吲哚衍生物的药物组合物、制备方法及用途
CN119059953A (zh) * 2024-08-27 2024-12-03 吉林大学 一种快捷合成1-(乙基磺酰基)氮杂环丁烷-3-酮的方法
WO2026061491A1 (zh) * 2024-09-20 2026-03-26 上海超阳药业有限公司 一种苯并吲哚衍生物的晶型、盐型及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6684907B2 (ja) * 2016-07-11 2020-04-22 オリンパス株式会社 内視鏡用クリップ装置
AU2017382176A1 (en) * 2016-12-21 2019-05-30 Biotheryx, Inc. Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof
WO2018169777A1 (en) * 2017-03-14 2018-09-20 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
PL3644999T3 (pl) * 2017-06-30 2023-05-08 Celgene Corporation Kompozycje i sposoby zastosowania 2-(4-chlorofenylo)-n-((2-(2,6-dioksopiperydyn-3-ylo)-1-oksoizoindolin-5-ylo)metylo)-2,2-difluoroacetamidu
TWI793151B (zh) * 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
CN109422753B (zh) * 2017-09-03 2021-12-31 上海美志医药科技有限公司 一类具有抑制并降解酪氨酸蛋白激酶jak1或jak2活性的化合物
EP3725771B1 (en) * 2017-12-13 2026-02-04 Shanghaitech University Alk protein degradation agent and anti-tumor application thereof
CA3101335C (en) * 2018-06-13 2024-01-09 Biotheryx, Inc. Fused thiophene compounds
CA3101338A1 (en) * 2018-06-13 2019-12-19 Biotheryx, Inc. Aminoamide compounds
AU2019323446B2 (en) * 2018-08-22 2025-01-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
WO2020173440A1 (en) * 2019-02-27 2020-09-03 Cullgen (Shanghai), Inc. Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use
US20230093099A1 (en) * 2019-04-02 2023-03-23 Cullgen (Shanghai), Inc. Compounds and methods of treating cancers
MX2021014345A (es) * 2019-05-24 2022-01-06 Biotheryx Inc Compuestos dirigidos a proteinas y composiciones farmaceuticas de los mismos, y sus aplicaciones terapeuticas.
EP4041231A1 (en) * 2019-10-09 2022-08-17 Monte Rosa Therapeutics AG Isoindolinone compounds

Similar Documents

Publication Publication Date Title
AU766081B2 (en) Phthalazine derivatives for treating inflammatory diseases
CN105473581B (zh) 作为溴结构域抑制剂的新取代的双环化合物
JP5843861B2 (ja) Axl阻害剤としての薬学的に活性な化合物
JP4516690B2 (ja) 血管形成阻害活性を有するイソキノリン誘導体
CN101558040B (zh) 用作蛋白激酶抑制剂的二氢吡啶衍生物
JP2020521740A5 (enExample)
CN103508961B (zh) 抗肿瘤药物
JP4216196B2 (ja) Npyアンタゴニストとしてのキノリン誘導体
JP4092203B2 (ja) 新規のシクロオキシゲナーゼ2選択的阻害剤としての置換アリール化合物、組成物、および使用方法
JP2004521087A5 (enExample)
WO2014080290A2 (en) Cyclic amines as bromodomain inhibitors
CN102812006A (zh) 新型抗疟疾试剂
JP2011521968A5 (enExample)
CN103025731A (zh) 作为alk5和/或alk4抑制剂的2-吡啶基取代的咪唑
WO2005009971A1 (ja) キノロン誘導体又はその塩
JP2006507355A5 (enExample)
TW200925154A (en) Phenylacetic acid compound
WO2004029049A1 (ja) 2-アシルアミノチアゾール誘導体の新規な塩
CN121013856A (zh) Egfr降解剂、其药物组合物及其用途
JP2020535172A5 (enExample)
TW200927127A (en) Agent for overcoming resistance to anti-cancer agent
CN109111438A (zh) 用于ido抑制剂的脒类化合物
WO2012174856A1 (zh) 一类可用于口服的凝血酶抑制剂及其制法以及医药用途
JP2021531320A5 (enExample)
JP6689887B2 (ja) 新規アミドヘテロアリールアロイルヒドラジドエチン